LFG
KRYS icon

Larson Financial Group’s Krystal Biotech KRYS Stock Holding History

Larson Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
27
+11
+69% +$3.29K ﹤0.01% 2401
2026
Q1 		$4.13K Sell
16
-1
-6% -$266 ﹤0.01% 2685
2025
Q4 		$4.19K Hold
17
– – ﹤0.01% 2525
2025
Q3 		$3K Buy
17
+15
+750% +$2.25K ﹤0.01% 2542
2025
Q2 		$275 Buy
+2
New +$294 ﹤0.01% 2996

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Larson Financial Group's KRYS Position: Q2 2026 in Review

Larson Financial Group increased its Krystal Biotech (KRYS) stake by 69% in Q2 2026, buying an estimated $3.29K and bringing the position to 27 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Larson Financial Group first reported a position in KRYS in Q2 2025 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Larson Financial Group held 27 shares of Krystal Biotech worth $10K as of Q2 2026.
  • Larson Financial Group bought 11 Krystal Biotech shares in Q2 2026, an estimated $3.29K.
  • Krystal Biotech made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2401 holding.
  • Larson Financial Group first reported a position in Krystal Biotech in Q2 2025 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.